EMA's updated QRD Appendix V puts ADR reporting wording back on PV teams' checklists

What happened

On 3 November 2026 EMA published Appendix V of its QRD documentation. The document covers the standard statement and contact details for reporting suspected adverse reactions in product information. The agency's listing does not say what has changed compared with the previous version, so any claim about specific amendments would be speculation.

The QRD (Quality Review of Documents) templates are the framework EMA uses to standardise the structure and wording of product information in the EU. In general terms, the reporting statement they provide appears in the summary of product characteristics and the package leaflet, and it points patients and healthcare professionals to the right reporting route. Appendix V is the part that deals with that statement and its contact details.

Why a reference document matters

Reporting wording looks like a clerical matter, but it sits at the front end of the pharmacovigilance system. If a leaflet or label sends a patient or clinician to the wrong place, or uses outdated wording, reports are delayed or never reach the competent authority or the marketing authorisation holder (MAH).

This is more than a hypothetical concern given what regulators were handling in the same week. Both the Italian regulator AIFA and the Slovak regulator ŠÚKL published Direct Healthcare Professional Communications (DHPCs) on Respreeza. AIFA's notice says CSL Behring reported stopper defects in certain batches that could prevent administration or allow microbial contamination. ŠÚKL describes possible compromised injection vial integrity that could lead to a missed dose or potential infection. Neither record gives case counts, so the scale of any patient impact is not known from the material available.

Those notices show how a quality defect turns into a safety communication. Clinicians and patients are then asked to act on the information, and reports of missed doses, administration problems or infections have to travel through functioning channels. Clear, current reporting instructions in the product information support that flow.

Regulatory context: batches, signals and traceability

Greece's EOF reports that EMA's safety committee, PRAC, is examining rising allergic reaction reports linked to batches of normal human immunoglobulin medicines. EOF also notes a separate review of Deanxit. The records give no outcome for either review, and no timeline, so what PRAC will recommend is not yet known.

The immunoglobulin item is a reminder that batch-specific questions depend on the quality of individual case reports. When PRAC looks at reactions clustering by batch, it needs the batch number, product identification and a clear reaction description in each report. In general terms, a PRAC review can end in no change, a product information update, additional risk minimisation or other regulatory action. Which of these applies here has not been communicated.

Taken together, the three items run along a single line. The Respreeza notices are quality-driven communications with a patient safety angle, the immunoglobulin work is a batch-related safety review, and Appendix V governs how patients and clinicians are told to report what they see.

Who is affected

QPPVs and PV system owners at EU MAHs are the first audience. Appendix V feeds the product information that their organisations maintain, so regulatory affairs and labelling teams will need to determine whether existing texts remain aligned. Because the changes are not specified, that determination requires a side-by-side comparison with the previous version rather than reliance on summaries.

Companies handling plasma-derived and other biological products have an additional reason to check their processes. Batch identification in case intake, follow-up questionnaires and quality-complaint reconciliation all matter when batch-related reviews or DHPCs are active. Whether any given MAH is affected by the immunoglobulin review depends on its portfolio, and the records do not list products.

The CMS final rules published the same day (physician fee schedule, outpatient, home health) concern Medicare payment policy. The records do not connect them to pharmacovigilance reporting, so they are outside the scope of this analysis.

What to watch

First, whether EMA or national authorities explain the changes to Appendix V, for example through accompanying notes or a revision summary. Second, whether EMA sets any expectation for when updated wording must appear in product information. Neither is stated in the record. Third, the outcome of PRAC's immunoglobulin batch review and of the Deanxit review, and whether further national authorities issue Respreeza DHPCs beyond Italy and Slovakia.